Cognition Therapeutics Inc. (CGTX) Soars 31.45% on FDA Phase 3 Trial Approval

Cognition Therapeutics Inc. (CGTX) shares surged 31.45% today, reaching their highest level since December 2024, with an intraday gain of 96.23%.

The strategy of buying CGTX shares after reaching a recent high and holding for one week resulted in a significant underperformance. Over the past five years, the strategy delivered an 89.19% loss, with a Sharpe ratio of -0.56 and a maximum drawdown of -95.67%. The strategy's CAGR was -59.27%, indicating a substantial decline in value. The high volatility, with a 105.05% annualized volatility, also suggests that this strategy carried significant risk.

Cognition Therapeutics' stock has seen significant increases due to the positive outcomes of their end-of-Phase 2 meeting with the FDA regarding their Alzheimer's drug, Zervimesine (CT1812). This meeting, held on July 9, 2025, reviewed the promising Phase 2 study results, which had previously shown a ~40% mean improvement in cognitive measures compared to placebo over six months. The successful discussions with the FDA have paved the way for Phase 3 trials, contributing to a surge in the company's stock.

The positive outcomes from the Phase 2 study and the subsequent meeting with the FDA have been pivotal in driving investor confidence. The drug's efficacy in improving cognitive measures has been a key factor in the stock's performance, as it indicates a potential breakthrough in the treatment of Alzheimer's disease. The FDA's approval for Phase 3 trials is a significant milestone for Cognition Therapeutics, as it brings the drug one step closer to market.

Investors are optimistic about the future prospects of Cognition Therapeutics, given the promising results of Zervimesine and the company's progress in clinical trials. The successful Phase 2 study and the FDA's approval for Phase 3 trials have positioned Cognition Therapeutics as a leader in the development of Alzheimer's treatments. The company's stock surge reflects the market's positive sentiment towards its potential to revolutionize the treatment of this debilitating disease.